Pfizer beats Q2 estimates with $14.7B revenue and $0.78 EPS. Management showed extreme confidence by raising full-year EPS guidance. See more on PFE stock here.

We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Pfizer Inc. (NYSE:PFE) is one of the ...

Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned.

Drugmaker Pfizer ($PFE) recently shared disappointing news about its experimental drug for sickle cell disease, inclacumab. In a late-stage ...

In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal ...

AstraZeneca's oncology sales jump 18% in second-quarter 2025, fueled by key drugs and new launches like Truqap and Datroway.

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. has initiated a study titled ‘Post-Approval Safety Monitoring ...

Many high-yield S&P 500 stocks are risky, but 19 'safer' dividend dogs have strong free cash flow to support payouts and are ...

Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in ...

Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

The FDA’s announcement of Papzimeos’ approval contained an unusual quote from newly reinstated CBER director Vinay Prasad. Elsewhere, Eli Lilly and Superluminal Medicines struck a deal.